RIGImmune Inc.

📍 Farmington, United States👥 12 employees💰 Last funded Feb 2022
Biotechnology Research🌐 rigimmune.com
Website LinkedIn
RIGImmune is a biopharmaceutical research company focused on the development of innovative RNA therapeutics to prevent or treat serious respiratory diseases with high unmet clinical needs. The company was co-founded by the prominent scientists Drs. Akiko Iwasaki and Anna Pyle from Yale University to advance the development of a novel class of oligonucleotides called stem-loop RNA therapeutics or “SLRs,” which were discovered in Dr. Pyle’s laboratory. To effectively deliver these RNA compounds without requiring lipid nanoparticle encapsulation, RIGImmune internally developed a proprietary nano-emulsion delivery technology platform named NEED™ and collaborates with SubIntro, which was co-founded by the prominent research scientists and successful respiratory drug and formulation developers, Drs. Garth Rapeport, Kazuhiro Ito, and Jag Shur. RIGImmune’s lead products aim to enhance the innate immune response against viral respiratory diseases, and treat cystic fibrosis, respectively. More information is available at: rigimmune.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in RIGImmune Inc.?
RIGImmune Inc. has 1 investors on record on gritt.io.
When did RIGImmune Inc. last raise funding?
The most recent investment in RIGImmune Inc. recorded on gritt.io was in February 2022.
What industry is RIGImmune Inc. in?
RIGImmune Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is RIGImmune Inc. based?
RIGImmune Inc. is headquartered in Farmington, United States.